Correspondence 0001104659-24-014967 from Bio Green Med Solution, Inc. (BGMS)

Bio Green Med Solution, Inc.
Date: Feb. 12, 2024 · CIK: 0001130166 · Accession: 0001104659-24-014967

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-276623

Date

February 12, 2024

Author

Cyclacel

Form

CORRESP

Company

Bio Green Med Solution, Inc.

Letter

Via Edgar United States Securities and Exchange Commission Division of Corporation Finance Attn: Jessica Dickerson and Laura Crotty Registration Statement on Form S-1 (File No. 333-276623) Request for Acceleration

Re: Cyclacel Pharmaceuticals, Inc.

Dear Ms. Dickerson and Ms. Crotty:

This letter is sent on behalf of Cyclacel Pharmaceuticals, Inc. (the “Company”) in connection with the above-referenced Registration Statement on Form S-1 (the “Registration Statement”) filed with the Securities and Exchange Commission (the “Commission”) by the Company pursuant to the Securities Act of 1933, as amended (the “Securities Act”). Pursuant to Rule 461 promulgated under the Securities Act, the Company hereby requests that the effective date of the Registration Statement be accelerated to 4:00 p.m., Eastern Time, on February 13, 2024, or as soon thereafter as practicable.

Please contact Jeffrey Schultz of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., at (212) 935-3000, with any questions you may have concerning this request.

Sincerely,
Cyclacel
Pharmaceticals, Inc.

Show Raw Text

CORRESP
1
filename1.htm

February 12, 2024

Via
Edgar

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

  Attn:
  Jessica Dickerson and Laura Crotty

  Re:
  Cyclacel Pharmaceuticals, Inc.

Registration Statement
on Form S-1 (File No. 333-276623)

Request for Acceleration

Dear Ms. Dickerson and
Ms. Crotty:

This letter is sent on
behalf of Cyclacel Pharmaceuticals, Inc. (the “Company”) in connection with the above-referenced Registration Statement
on Form S-1 (the “Registration Statement”) filed with the Securities and Exchange Commission (the “Commission”)
by the Company pursuant to the Securities Act of 1933, as amended (the “Securities Act”). Pursuant to Rule 461 promulgated
under the Securities Act, the Company hereby requests that the effective date of the Registration Statement be accelerated to 4:00 p.m.,
Eastern Time, on February 13, 2024, or as soon thereafter as practicable.

Please contact Jeffrey
Schultz of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., at (212) 935-3000, with any questions you may have concerning this request.

    Sincerely,

    Cyclacel
    Pharmaceticals, Inc.

    By:
    /s/
    Paul McBarron

    Name:
    Paul
    McBarron

    Title:
    Executive
    Vice President-Finance,

    Chief
    Financial Officer and Chief Operating Officer

  cc:
  Jeffrey Schultz, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

SecProbe.io